A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

To join this study, you need to be at least 18 years old. If you have been diagnosed with multiple myeloma, your illness must have come back or not responded to previous treatments. Specifically, you would have already tried a few standard types of treatment, like a proteasome inhibitor, an IMiD agent, and an anti-CD38-based therapy.

For multiple myeloma, your overall health should be good enough for you to manage daily activities without too much difficulty. Doctors will also need to be able to measure your disease, for example, by looking at levels of certain proteins in your blood or urine. If you have AL amyloidosis, you would have already received treatment for it, and your medical team would consider you not suitable for other available treatments with proven benefits.

If you decide to take part in this study, you will receive the study medication, JNJ-79635322. The study is divided into two parts: an initial dose-finding part (Part 1) and a later part that expands on this to look at more people (Part 2). Regardless of which part you are in, you will have regular visits to the clinic. These visits will involve various assessments, such as blood tests, urine tests, physical examinations, and possibly scans, to check on your health, how the medication is affecting you, and how your condition is responding.

The frequency and duration of these visits will depend on the specific stage of the study and your individual response, but they will likely be quite regular, especially at the beginning. You will also have follow-up appointments after you stop taking the study medication. The total duration of your participation will vary depending on your medical situation and the study's design. The study team will provide you with a detailed schedule of visits and procedures if you are considered for participation.